Joshua J. Neumiller, PharmD, CDCES, of the American Diabetes Association, discusses pharmacists’ role in diabetes and CKD care at ASN Kidney Week 2026.
|Videos|July 23, 2015
Getting Comfortable with New Pharmacy Technologies
Daniel Kraft, MD, chair of medicine at Singularity University and chair/founder of Exponential Medicine, discusses how pharmacists can become more comfortable with new technology.
Advertisement
Daniel Kraft, MD, chair of medicine at Singularity University and chair/founder of Exponential Medicine, discusses how pharmacists can become more comfortable with new technology.
Advertisement
Related to this article
Jai Radhakrishnan, MD, MBBS, MS, FASN, discusses why IgG4-related kidney disease is often missed and what the MITIGATE subgroup data presented at ASN Kidney Week 2026 show.
The provider-administered IL-23 inhibitor improved ACR20 response vs placebo after 2 doses in the phase 3 INSPIRE-1 and INSPIRE-2 trials.
Two Kidney Week 2026 posters suggest remnant cholesterol–based markers may help stratify CKD severity and cardiovascular death risk on hemodialysis.
Treated patients also had fewer post-acute hospitalizations and deaths, but individuals without risk factors saw no benefit.
A pharmacy technician reflects on 3 patient encounters that reshaped his
understanding of what a real patient requires.
In a Korean cohort of 1861 patients with nondialysis CKD, intake below 0.6 g/kg per day was linked to more kidney failure and higher all-cause mortality.
A disease-modifying therapy for stage 3 T1D, a second once-weekly insulin, and automated insulin delivery for T2D mark a busy year in diabetes care.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Community Pharmacists Guide Patients New to Glucose Monitoring
2
FDA Approves Tildrakizumab for Adults With Psoriatic Arthritis
3
Long-Term Care Pharmacies Can Close the Flu Vaccination Gap Among Older Adults
4
Narrow Therapeutic Index Chemotherapy Dosing With eGFR: Safeguards for Oncology Pharmacists
5